Terms: = Kidney tumors AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Prognosis
116 results:
1. Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.
Xing Z; Xu H; Ai K; Deng H; Hong Y; Deng P; Wang J; Xiong W; Li Z; Zhu L; Li Y
Ann Surg Oncol; 2024 May; 31(5):3531-3543. PubMed ID: 38329657
[TBL] [Abstract] [Full Text] [Related]
2. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
3. Laparoscopic partial versus radical nephrectomy for localized renal cell carcinoma over 4 cm.
Sun ZJ; Liu F; Wei HB; Zhang DH
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17837-17848. PubMed ID: 37943356
[TBL] [Abstract] [Full Text] [Related]
4. The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms.
d'Izarny-Gargas T; Isnard P; Boudhabhay I; Buob D; Moktefi A; Linster C; Hummel A; Esteve E; Audard V; Lazareth H; Maroun N; Hertig A; Gosset C; Jouzel C; Permal S; Domenger C; Kosmider O; Rabant M; Karras A; Duong Van Huyen JP
Kidney Int; 2023 Dec; 104(6):1206-1218. PubMed ID: 37769965
[TBL] [Abstract] [Full Text] [Related]
5. Non-obstructive jaundice as paraneoplastic syndrome of prostate carcinoma: Systematic review of published cases.
Santandreu-Morales I; Redondo-Cerezo E; Martín-Enguix D
Med Clin (Barc); 2023 Mar; 160(5):206-212. PubMed ID: 36526448
[TBL] [Abstract] [Full Text] [Related]
6. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
[TBL] [Abstract] [Full Text] [Related]
7. Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy.
Yang W; Ma L; Dong J; Wei M; Ji R; Chen H; Xue X; Li Y; Jin Z; Xu W; Ji Z
Biomol Biomed; 2023 May; 23(3):471-482. PubMed ID: 36326180
[TBL] [Abstract] [Full Text] [Related]
8. Biphasic squamoid alveolar papillary renal cell carcinoma: A unique papillary renal cell carcinoma with distinctive morphology, immunophenotype and molecular genetic features.
Li Y; Wu X; Yang J; Jiang Y; Li Y; Zhang W; Yu W
Pathol Res Pract; 2022 Nov; 239():154120. PubMed ID: 36201928
[TBL] [Abstract] [Full Text] [Related]
9. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.
Sweeney PL; Jang A; Halat SK; Pal SK; Barata PC
Cancer Treat Res Commun; 2022; 33():100639. PubMed ID: 36162322
[TBL] [Abstract] [Full Text] [Related]
10. Factors affecting prognosis of the patients with severe hyponatremia.
Turkmen E; Karatas A; Altindal M
Nefrologia (Engl Ed); 2022; 42(2):196-202. PubMed ID: 36153916
[TBL] [Abstract] [Full Text] [Related]
11. A nomogram integrating ferroptosis-and immune-related biomarker for prediction of prognosis and diagnosis in kidney renal clear cell carcinoma.
Xing XL; Liu Y; Liu JH; Zhou HF; Zhang HR; Zuo Q; Bu P; Duan T; Zhou Y; Xiao ZQ
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6176-6186. PubMed ID: 36111917
[TBL] [Abstract] [Full Text] [Related]
12. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Negishi T; Nakagawa T; Nishiyama N; Kitamura H; Okajima E; Furubayashi N; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Nakamura M
Jpn J Clin Oncol; 2022 Dec; 52(12):1430-1435. PubMed ID: 36093731
[TBL] [Abstract] [Full Text] [Related]
13. Primary Tumor Shrinkage and the Effect on metastatic Disease and Outcomes in Patients With Advanced kidney Cancer With Intermediate or Poor prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
Iacovelli R; Ciccarese C; Maruzzo M; Atzori F; Galli L; Scagliarini S; Massari F; Verzoni E; Cannella A; Maratta MG; Caserta C; Bimbatti D; Deppieri FM; Dessi M; Paolieri F; Riccardi F; Bracarda S; De Giorgi U; Basso U; Tortora G; Procopio G
Clin Genitourin Cancer; 2022 Oct; 20(5):498.e1-498.e9. PubMed ID: 35768316
[TBL] [Abstract] [Full Text] [Related]
14. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
[TBL] [Abstract] [Full Text] [Related]
16. TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC.
Sun H; Zheng J; Xiao J; Yue J; Shi Z; Xuan Z; Chen C; Zhao Y; Tang W; Ye S; Li J; Deng Q; Zhang L; Zhu F; Shao C
Cell Death Dis; 2022 May; 13(5):450. PubMed ID: 35546143
[TBL] [Abstract] [Full Text] [Related]
17. Cabozantinib as First-line Treatment in Patients With metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study).
Procopio G; Sepe P; Claps M; Buti S; Colecchia M; Giannatempo P; Guadalupi V; Mariani L; Lalli L; Fucà G; de Braud F; Verzoni E
JAMA Oncol; 2022 Jun; 8(6):910-913. PubMed ID: 35420628
[TBL] [Abstract] [Full Text] [Related]
18. Small cell variant of chromophobe renal cell carcinoma: Clinicopathologic and molecular-genetic analysis of 10 cases.
Rogala J; Kojima F; Alaghehbandan R; Ptakova N; Bravc A; Bulimbasic S; Perez Montiel D; Slisarenko M; Ali L; Kuthi L; Pivovarcikova K; Michalova K; Bartovic B; Bartos Vesela A; Dolejsova O; Michal M; Hes O
Bosn J Basic Med Sci; 2022 Jul; 22(4):531-539. PubMed ID: 35276058
[TBL] [Abstract] [Full Text] [Related]
19. cmet: a prognostic marker in papillary renal cell carcinoma?
Erlmeier F; Bruecher B; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Mondorf Y; Ivanyi P; Mikuteit M; Steffens S;
Hum Pathol; 2022 Mar; 121():1-10. PubMed ID: 34998840
[TBL] [Abstract] [Full Text] [Related]
20. The prognostic significance of controlling nutritional status (CONUT) score for surgically treated renal cell cancer and upper urinary tract urothelial cancer: a systematic review and meta-analysis.
Peng L; Meng C; Li J; You C; Du Y; Xiong W; Xia Z; Cao D; Li Y
Eur J Clin Nutr; 2022 Jun; 76(6):801-810. PubMed ID: 34815539
[TBL] [Abstract] [Full Text] [Related]
[Next]
